U.S. Capital Markets Stock News

On 27 June 2026, Golar LNG Limited was added to both the Russell 2000 Value-Defensive Index and the Russell 2000 Defensive Index, expanding its presence in key US equity benchmarks. This dual inclusion could increase the company’s visibility among institutional investors and index-tracking funds that focus on defensive and value-oriented exposures. We’ll now examine how Golar LNG’s entry into these Russell 2000 defensive indexes may influence its existing long-term FLNG investment...

Tariff headlines are back in focus, and this time the pressure is squarely on import costs for U.S. consumers and businesses. With Virginia and other states pushing back against broad U.S. tariffs, investors are weighing what heavier trade frictions and higher prices could mean for different parts of the market. Domestic focused stocks that rely less on imported inputs can appear relatively insulated when trade tensions rise, while others may face higher cost pressure or sentiment swings...

In late June 2026, Oruka Therapeutics, Inc. was removed from several Russell value and microcap indices and simultaneously added to multiple Russell growth benchmarks, including the Russell 2000 and Russell 3000 growth indices. This shift effectively reclassifies Oruka Therapeutics in major index frameworks from a value- and microcap-oriented profile toward a growth-focused small-cap identity, which can materially influence how institutional investors and index-tracking funds view the...

Jefferies Financial Group Inc. recently priced and completed several senior unsecured, fixed-rate note offerings in euros and U.S. dollars, including €850.00 million of 4.500% notes due 2033, to raise funding for general corporate purposes. At the same time, the firm is facing SEC scrutiny and a law firm investigation over disclosures related to losses from its Point Bonita Capital exposure to the bankrupt First Brands Group, while also being removed from multiple Russell growth...

In late June 2026, National HealthCare Corporation amended its credit agreement with Bank of America, expanding its senior unsecured revolving credit facility from US$50,000,000 to US$75,000,000 and drawing US$475,000,000 under a term loan plus US$55,000,000 under the revolver to help fund a transaction. Around the same time, National HealthCare was added to several Russell growth and small-cap benchmarks, a change that can increase its visibility with index-tracking funds and institutional...

In recent days, First Industrial Realty Trust reported strong Q1 2026 results, with earnings per share of US$1.08 significantly exceeding forecasts, and attracted renewed coverage from several investment firms highlighting demand for its logistics properties. This combination of outperformance against expectations and fresh analyst attention has sharpened the focus on how First Industrial is positioned within the industrial real estate market. With Q1 earnings materially ahead of forecasts,...

Fitzroy Island Resort recently announced it has replaced a fragmented set of legacy hospitality systems with a unified Agilysys platform, cutting night audit workloads in half and automating key financial reporting tasks. Staff adoption has been so strong that employees resisted any rollback to the old software, while the resort now also uses Agilysys Book and Reserve to track Great Barrier Reef visitor metrics and coordinate conservation-related travel. We’ll now examine how this rapid,...

Recently, Nutex Health Inc. announced that its microhospital model, which makes extensive use of No Surprises Act arbitration, has helped drive revenue to roughly triple and profits to grow by a very large multiple. This approach shifts the company’s core economics toward reimbursement outcomes and payer disputes, making arbitration performance almost as important as patient volumes or new facility openings. Next, we’ll examine how Nutex’s arbitration-driven microhospital success reshapes...

Royalty Pharma plc (NasdaqGS:RPRX) was added to both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index on 27 June 2026, highlighting its classification among larger, relatively more defensive US equities. This dual index inclusion can raise Royalty Pharma’s visibility with institutional investors and index-tracking funds, potentially increasing demand for its shares and reinforcing its profile as a defensive healthcare royalty specialist. Next, we’ll examine how...

Pure Cycle (PCYO) has posted its Q3 2026 numbers with total revenue of about US$8.2 million and basic EPS of US$0.12, set against trailing twelve month revenue of roughly US$33.7 million and EPS of US$0.61, underpinned by 8.2% earnings growth over the past year. Over recent quarters, the company has seen revenue move from around US$5.2 million with EPS of US$0.03 in Q2 2025 to US$11.2 million with EPS of US$0.25 in Q4 2025, then to US$8.2 million and EPS of US$0.12 in Q3 2026. This has left...

Butler National (BUKS) has put up a clean set of FY 2026 numbers, with fourth quarter revenue at US$27.7 million and basic EPS of US$0.09, alongside trailing twelve month revenue of US$98.0 million and EPS of US$0.34 that sit against reported earnings growth of 74.8% over the past year. Over recent periods the company has seen revenue progress from US$83.97 million on a trailing basis in FY 2025 to US$98.0 million in FY 2026. EPS over the same trailing window moved from US$0.19 to US$0.34,...

Wayfair's share price has rebounded in the last year, but with the stock still down 68.5% over five years and screening as overvalued on market multiples, the current level raises questions about how much of the recovery story is already reflected in the price. Over the past five years, Wayfair has delivered a total return that is down 68.5%, which highlights how deep the earlier drawdown was despite the more recent strength. Recent optimism around improving earnings expectations can support...

PriceSmart (PSMT) has released its Q3 2026 results, reporting revenue of about US$1.5b, basic EPS of roughly US$1.31 and net income, excluding extra items, of US$39.7m. The company’s quarterly revenue has moved from US$1.33b in Q4 2025 to US$1.38b in Q1 2026, US$1.50b in Q2 2026 and US$1.48b in Q3 2026. Over the same period, basic EPS ranged from US$1.02 to US$1.62, giving investors a clear view of top line scale and earnings power to track. With trailing 12 month EPS of about US$5.22 and a...

Clinical momentum and index changes frame Dianthus Therapeutics stock story Dianthus Therapeutics (DNTH) has kicked off its global Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis, while the stock was recently removed from several Russell value and growth benchmarks. The EMERGE trial will enroll about 195 acetylcholine receptor antibody positive generalized Myasthenia Gravis participants and compare subcutaneous claseprubart against placebo, with the Myasthenia Gravis...

Arbutus Biopharma stock has delivered a strong 126.4% return over the past three years, yet its current valuation checks and market multiples suggest the shares are not a clear bargain at recent levels. Over the last three years, Arbutus Biopharma has returned 126.4%, which puts extra focus on whether the current share price already reflects much of the good news investors are hoping for. Expectations around the company’s ability to turn its pipeline and research into durable cash flows can...

AZZ (AZZ) has opened fiscal 2027 with Q1 revenue of $448.5 million and basic EPS of $1.74, setting the tone for how its earnings story is evolving after a mixed year of growth and margin shifts. The company has seen quarterly revenue move from $421.9 million and EPS of $5.71 in Q1 2026 to $448.5 million and $1.74 in Q1 2027, against a backdrop where trailing 12 month EPS was $6.62 and net income was $198.4 million. This frames a results season in which investors are watching how profit...

Helen of Troy (HELE) opened fiscal Q1 2027 with revenue of US$402.1 million and basic EPS of US$1.54, while the trailing twelve months show revenue of US$1.8 billion and a basic EPS loss of US$17.87, highlighting the gap between the latest quarter and the broader period. Over the past few reported quarters, revenue has ranged from US$371.7 million to US$512.8 million and EPS has swung from a loss of US$19.65 to a profit of US$2.22. This sets the backdrop for how investors read this latest...

GATX (GATX) is in focus ahead of its 2026 second quarter earnings report, scheduled before the market opens on July 30, with a conference call and webcast for investors later that morning. See our latest analysis for GATX. At a share price of $174.95, GATX has seen modest short term share price momentum, with its 1 day and year to date share price returns in positive territory. Longer term total shareholder returns over 1, 3 and 5 years indicate that most gains have accrued over time rather...

Index reshuffle puts Kaiser Aluminum in focus Kaiser Aluminum (KALU) reported record first quarter 2026 net sales, conversion revenues, net income and adjusted EBITDA, alongside guidance for further improvement this year, just as the stock shifted across several Russell index classifications. For investors, this combination of strong recent performance and index changes raises practical questions about how Kaiser Aluminum might fit within portfolios that track value, growth or defensive...

With the Federal Reserve turning hawkish again and inflation sitting at 4.2%, investors are rethinking where they want their money. Rising rates, volatile growth stocks, and a rotation toward more resilient earnings stories are reshaping the opportunity set. This article looks at how that backdrop and the recent Fed pivot could affect U.S. Financial Services Stocks, and why some large, financially healthy companies may be better positioned than others. Below, you will find 3 stocks from our...

Innovex International (INVX) has just been added to multiple Russell growth indexes. This event can reshape who holds the stock as index funds and benchmarked investors adjust their portfolios. See our latest analysis for Innovex International. Over the past year Innovex International has combined a 10.01% year to date share price gain with a 54.03% total shareholder return. However, the 30 day share price return is down 11.85%, and the recent index additions appear to be resetting near term...

With major indexes riding an AI-fueled surge and the Buffett indicator sitting at a very high level relative to GDP, many investors are wondering where genuine value still exists and where risks might be building. This article looks at how that backdrop could affect a group of stocks flagged by a Value Stocks screener, focusing on low P/E and P/B ratios and a possible discount to intrinsic value. Below, you will find 3 stocks that the recent market setup may treat as relative beneficiaries...

In recent months, AllianceBernstein Holding has advanced efforts to lift profitability through office relocations and other margin accretion measures, while broadening its private markets platform via partnerships and new products in private credit, real estate, and alternative strategies. This push into higher-fee private markets and operational efficiency has sharpened investor focus on how the firm may reshape its earnings mix and risk profile. Next, we’ll examine how AllianceBernstein’s...

Microchip Technology has made its MPLAB XC Pro Compilers and Machine Learning Development Suite available for free to all users worldwide. The move also covers its functional safety compilers, broadening access to tools for safety-critical and AI-enabled embedded applications. This shift is expected to widen adoption of Microchip’s microcontroller platforms and deepen engagement with its development ecosystem. For investors watching NasdaqGS:MCHP, this software decision adds an important...